<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01942447</url>
  </required_header>
  <id_info>
    <org_study_id>UKT-FMT</org_study_id>
    <secondary_id>UKT</secondary_id>
    <nct_id>NCT01942447</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis</brief_title>
  <acronym>TOCSIN</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      The host gastrointestinal microbiota is significantly influenced by antibiotic treatment&#xD;
      which might favor Clostridium difficile infection (CDI), a frequent cause of community- and&#xD;
      hospital-acquired, potentially life-threatening diarrhoea. CDI is followed by recurrence in&#xD;
      19-35% of patients despite adequate first line antimicrobial therapy. Currently there is no&#xD;
      standardized therapy of recurrent or refractory CDI, but recent studies show remarkable&#xD;
      effects of fecal microbiota transplantation (FMT).&#xD;
&#xD;
      In the current project, we aim to ideally match host and donor for FMT success in recurrent&#xD;
      or refractory CDI. We will establish a clinical standard operating protocol for FMT, we will&#xD;
      evaluate its safety and efficacy, and the patient acceptance and quality of life before and&#xD;
      after FMT. We will analyse persistence of the donor microbiota within the recipient, define&#xD;
      predictive clinical recipient and donor factors for FMT success and correlate them with&#xD;
      microbial host and donor metagenomics.&#xD;
&#xD;
      We hypothesize that our work will yield novel, individualized strategies for recurrent or&#xD;
      refractory CDI. In perspective, our results may be expanded to treatment of other inflammory&#xD;
      bowel diseases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of diarrhea</measure>
    <time_frame>2 weeks</time_frame>
    <description>Resolution of diarrhea</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient acceptance</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Persitence of FMT</measure>
    <time_frame>26 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Clostridium Difficile</condition>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>FMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FMT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vancomycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FMT</intervention_name>
    <arm_group_label>FMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  recurrent or refractory CDI&#xD;
&#xD;
          -  previous antimicrobial therapy includes at least on course of vancomycin 4x125 (or&#xD;
             higher doses) for at least 7d&#xD;
&#xD;
          -  CDI, defined as: 3 or more loose bowel movements/d AND (presence of C.diff. toxin in&#xD;
             stools or toxin producing C. diff. strain) OR (endoscopic or histologic evidence of&#xD;
             pseudomembraneous colitis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no informed consent&#xD;
&#xD;
          -  no ability to provide informed consent&#xD;
&#xD;
          -  immune suppression (continuous immune-suppressive drugs; steroids:&#xD;
             prednisolone-equivalent &gt; 20 mg for 14d or longer)&#xD;
&#xD;
          -  lack of appropriate donor&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martin Goetz, Prof</last_name>
    <email>martin.goetz@med.uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Martin Goetz, Prof.</last_name>
      <email>martin.goetz@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Martin Goetz, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>September 5, 2013</study_first_submitted>
  <study_first_submitted_qc>September 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2013</study_first_posted>
  <last_update_submitted>October 10, 2013</last_update_submitted>
  <last_update_submitted_qc>October 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Martin Goetz</investigator_full_name>
    <investigator_title>Univ.-Prof. Dr. med. Martin Goetz</investigator_title>
  </responsible_party>
  <keyword>Fecal microbiota transplantation</keyword>
  <keyword>microbiota</keyword>
  <keyword>clostridium difficile</keyword>
  <keyword>clostridium difficile infection</keyword>
  <keyword>Efficacy of FMT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

